Abstract OBJECTIVES: Preoperative evaluation of patients with suspected or confirmed lung cancer consists of clinical and radiological staging. Malignant pleural effusion is a poor prognosticator in non-small-cell lung cancer. Pleural ultrasound (PU) allows for the assessment of pleural effusion, providing real-time guidance for its aspiration and cytological analysis. Pleural Ultrasonography in Lung Cancer (PULC) as an adjunct to physical examination has the potential to improve preoperative staging of non-small-cell lung cancer during first surgical encounter by allowing the evaluation of previously unassessed pleural effusion.
INTRODUCTION
Lung cancer remains the leading cause of mortality from malignant disease worldwide [1] . The thoracic surgeon's preoperative evaluation and initial consultation in patients who are to undergo operative staging or resection for lung cancer is multidimensional and involves detailed history taking, physical examination and review of imaging studies. An important element of both staging and preoperative evaluation consists of the evaluation of the pleural space for malignant pleural effusion. Malignancy is the most common cause of unilateral pleural effusion in the USA [2] , lung carcinoma being the most common underlying pathology, accounting for one-third of all malignant effusions [3] . Pleural space evaluation is typically performed with computed tomography (CT) scan, which does not allow for the collection of cytological material from pleural effusions. Furthermore, preconsultation CT scans are sometimes performed at an earlier setting, making it impossible to perform real-time pleural space assessment when there is a long lag time between the CT scan and consultation.
Portable ultrasonography is generally considered equivalent to a chest CT scan for the identification of pleural effusions [4, 5] , having the additional advantages of sparing the patient ionizing radiation, allowing a dynamic assessment of the regions of interest and instantaneously yielding results to the clinician, who is able to use the device at the patient's bedside. When aspiration is feasible, pleural ultrasound (PU) can provide a real-time guidance for needle thoracentesis and decrease the risk of potential morbidity [6] . In the American Joint Committee on Cancer Non-Small Cell Lung Cancer Staging system (7th edition), a radiologically visualized pleural effusion with positive cytology in a patient with lung cancer increases the TNM stage to M1a or Stage IV, which reorients the patient towards medical (non-operative) management [7] . To our knowledge, there has been no prospective study assessing pleural effusions with ultrasonography in the preoperative setting in patients with lung cancer. In this prospective cohort, we hypothesized that PU with evaluation and aspiration of pleural effusion improves preoperative staging and alters decision-making patterns for lung cancer patients in terms of testing, therapy and operative planning.
MATERIALS AND METHODS
From 1 July 2010 to 30 September 2010 (3 months), all patients with the new or presumed diagnosis of lung cancer seen in the thoracic surgery preoperative clinic at the Centre Hospitalier de l'Universite de Montreal-Notre-Dame Hospital, University of Montreal, Montreal, Quebec, Canada, were prospectively enrolled. Patients <18 years old or unable to consent were excluded. Written informed consent was obtained in the thoracic surgery preoperative clinic. The study consisted of a prospective cohort study (clinicaltrials.gov identifier: NCT01141946). This study was approved by the institutional review board of the Centre de Recherche du CHUM. Baseline patient characteristics (age, body mass index and comorbidities) and imaging results were obtained from hospital records and patient interviews and recorded on standardized study report forms. Surgical procedure and operative details were obtained from patient electronic medical records.
Patients underwent standard history and physical examination by the treating thoracic surgeon. Pleural ultrasonography (US) was performed by the attending general thoracic surgeon, resident or medical student during or after physical examination. All ultrasonographic examinations were completed using a GE LOGIQe portable ultrasound machine (GE Healthcare, Milwaukee, WI, USA) with both cardiac GE 3S Convex (4 MHz) and vascular 12L-RS Linear (10 MHz) probes (GE Healthcare). Ultrasonography was performed in a sitting position. In patients unable to tolerate a sitting position, PU examination was performed in a 45-degree supine position. With each probe, the anterior, lateral and posterior costodiaphragmatic angles of each hemithorax were examined through the hepatic or splenic window. This was performed in all views between the anterior axillary line and the paravertebral line.
Pleural effusion was confirmed with visualization of an anechoic interpleural space >0.5 mm thick in the axial plane of the body showing movement coordinated with respiration, change in the patient position or heartbeat (lung pulse sign) [8] . If a pleural effusion was found, its upper and lower limits were identified and its size (lung-diaphragm distance and maximum depth of the effusion), echogenicity and the presence of swirling pattern or fibrinous septa were noted.
In cases demonstrating a punctionable pleural effusion, anteroposterior, lateral and decubitus chest X-rays were obtained in order to confirm its presence, and percutaneous pleural aspiration was performed under ultrasonographic guidance using a sterile technique with local anaesthesia (5-10 cc xylocaine with 2% epinephrine). Liquid was extracted with a 25-G needle and 60 ml syringes. An attempt was made to aspirate 20 ml or more of pleural fluid, in order to allow an adequate yield for cytological examination [9] . Ten millilitres of fluid were sent for biochemical analysis and the rest of the fluid was mixed with CytoLyt solution (Cytyc Corporation, Boxborough, MA, USA) for cytological analysis. Biochemical assessment included pleural fluid protein, LDH and pH. Cytology analysis was performed using a cell spread and hematoxylin phloxine saffron cell block.
Relative contraindications to aspiration included a minimal effusion with axial thickness under 1 cm from the lung to chest wall on a lateral decubitus chest X-ray [3] . Absolute contraindications to aspiration included: proven pulmonary hypertension, International Normalized Ratio superior to 1.8, prothrombin time longer than 50 s, platelet count under 50 000, anticoagulant medication (warfarin, clopidogrel and heparin), steroid therapy and active cutaneous infection over the proposed puncture site.
The pre-Pleural Ultrasonography in Lung Cancer (PULC) clinical tumoural stage was inferred from the most recent CT scan, positron emission tomography (PET) scan, bone scan, pleural aspiration done independently of the PULC study, bronchoscopy, transthoracic biopsy, endobronchial or oesophageal ultrasound or video-assisted thoracoscopic surgical (VATS) staging; should these examinations have taken place prior to PU. Data about procedures and morbidity surrounding PULC (lactate dehydrogenase) was recorded prospectively. Surgical data pertinent to staging and postoperative morbidity were also recorded. Patient demographic and clinical variables were obtained from patient interview and clinical examination prior to PULC examination. Table 1 . Before PU examination, 3 of the 45 patients had a pleural effusion documented on imaging; however, none had undergone pre-PULC pleural aspiration.
Thirteen (29%) patients displayed pleural effusions on ultrasonographic examination. Ten (22%) of the effusions had not been recognized on imaging prior to PU. No effusion displayed homogeneous echogenicity or swirling pattern. A parenchymal pulmonary nodule was detected in 4 patients, in 3 of whom the lesion touched the visceral pleura, resulting in an adjacent pleural nodularity. While all parenchymal lesions had already been assessed radiologically, 2 of the adjacent pleural nodules had not been visualized prior to the PULC study. PU revealed 2 isolated pleural lesions, 1 of which had not been previously recognized radiologically. VATS later confirmed this last nodule to be an asbestosrelated pleural plaque. The mean time required to perform pleural ultrasonography was 15 ± 7 min.
Among the 13 effusions detected, 3 were adequate for safe pleural aspiration. No patient displayed any contraindication to pleural aspiration, and there were no complications related to the procedures. Cytological analysis yielded malignant cells in 1 of the 3 aspirates. Table 2 summarizes the different characteristics of the 3 collected aspirates. No aspirate displayed lymphocytosis or macroscopically visible pus. Positive PULC evaluation led to a change in preoperative clinical staging (M0 to M1a) in 10 (22%) patients and a change in pathological staging ( pleural fluid cytology positive) in 1 (2.2%) ( Table 1) . Table 3 presents the clinical course of the 10 patients in whom PULC diagnosed a previously unappreciated pleural effusion and thus, upgraded clinical stage to Stage IV. A discussion of the 3 patients in whom PULC allowed pleural aspiration follows. The first patient to undergo pleural aspiration had a previous CT Scan performed a year before the PULC study, showing a small right upper lobe 7 mm in density and no pleural effusion, corresponding to a pre-PULC T-stage of T1. The patient presented with dyspnoea and pleuritic chest pain. PULC exam revealed the presence of a large effusion displaying lung pulse sign as well as a right lung subpleural mass (Fig. 1) . Pleural aspiration was performed, yielding 200 ml of serous, straw-coloured fluid. Cytology showed malignant cells (Table 2) . After pleural drainage, a CT scan showed two lung lesions, one measuring 2.9 × 2.4 cm in the middle lobe and T1b  T2a  T1a  T3  T2a  T2  T3  T3  T3  Pre-PULC TNM stage   a   IIIB  IA  IB  IA  IIIA  IIIA  IB  IIB  IIIA another 6.4 × 2.6 cm in the right lower lobe (Fig. 2) . A transthoracic parenchymal lung biopsy performed under CT guidance demonstrated adenocarcinoma. A PET scan was then performed and detected ipsilateral rib invasion, and this patient's post-PULC T-stage was, therefore, T4. Stage upgrade from IIIB to IV lung cancer based on PULC spared this patient futile thoracotomy, and the care of this patient was transferred to the medical oncology service to receive palliative treatment.
The second patient to undergo pleural aspiration had a previous CT scan performed 3 months prior to PULC, showing a left upper lobe lesion measuring 3.5 × 3.0 × 2.6 cm with invasion of the visceral pleura, without pleural effusion, corresponding to a pre-PULC stage of T2a (Fig. 3A) . PULC performed in the preoperative clinic detected the left subpleural lesion as well as a pleural effusion and allowed puncture of 11 ml of serous fluid tinged with blood (Fig. 3B) . Laboratory analyses characterized the effusion as inflammatory and cytology was negative ( Table 2 ).
The third patient to undergo pleural aspiration had a previous CT scan performed 2 months before the PULC study, showing a left upper lobe lesion causing lobar atelectasis as well as pleural effusion, corresponding to a pre-PULC stage of T2a in the context of an overall clinical Stage IV (Fig. 4) . A transthoracic biopsy performed 1 month pre-PULC showed squamous cell carcinoma. PULC performed in the preoperative clinic detected a pleural effusion and allowed puncture of 8 ml of serous straw-coloured fluid, the cytology of which was negative (Table 2) .
Thirty-eight patients underwent surgical resection of their lung lesion, 7 were treated with chemo-radiotherapy and 1 died preoperatively. Pleural exploration by VATS or by thoracotomy confirmed the presence or absence of pleural effusion and pleural carcinomatosis seen on PULC in all patients having undergone surgical exploration. Among the 10 patients in whom PU demonstrated a previously unassessed pleural effusion, 6 underwent surgical resection. VATS was chosen as the first-intent operative approach in 4 of these patients ( Table 3) .
The patient in whom PULC demonstrated pleural carcinomatosis and a cytologically positive pleural effusion was sent to medical oncology and received palliative chemotherapy for TNM Stage IV disease. Six other patients were oriented towards nonsurgical care because of medical comorbidities and pulmonary function precluding surgery, independent of TNM stage. Table 4 lists the different histopathological diagnoses associated with the findings reached by the PULC procedure. All benign diagnoses were established at the time of surgery. One patient with a rightsided lesion who had displayed an ipsilateral parenchymal nodule reaching the pleura and an ipsilateral pleural effusion, which could not be punctured at the time of PULC examination, was diagnosed with fibrinous pleuritis following operative pleural biopsy, pleural fluid biochemistry and cytology.
DISCUSSION
To our knowledge, this is the first prospective study to evaluate the pleura with ultrasonography in the preoperative clinic in patients with potentially resectable lung cancer. Positive PULC evaluation has led to a change in preoperative clinical staging (M0 to M1a) in 10 (22%) patients and a change in pathological staging ( positive pleural fluid cytology) in 1 (2.2$) of 45 study participants. The presence of a previously unappreciated pleural effusion assessed using PULC implies a potentially worsened prognosis [10, 11] as well as a reorientation of preoperative investigations in 10 (22%) patients. In those patients, PULC may indicate the need for further investigation with regard to the assessed pleural effusion, including subsequent pleural aspiration if the effusion volume was insufficient at the time of the PULC exam, a second pleural tap or VATS assessment [2, 12] . The finding of a pleural effusion on ultrasonographic examination can also be utilized to orient surgical procedures towards VATS exploration of the pleural space prior to thoracotomy [13] . In this study, 4 of 6 surgical resections in patients with PULC-assessed pleural effusions were performed by VATS. The choice of operative approach was somewhat influenced by the finding of an effusion on PULC, but was also modulated by other case-specific factors and surgeon preference.
PULC has allowed the aspiration and cytological assessment of pleural effusion in 3 (6.6%) of 45 patients in this study. The tumoural T-stages of cancers that were associated with the 3 pleural effusions in this study were: (i) T3 with chest wall invasion, (ii) T2a involving the visceral pleura and (iii) T2a causing complete lobar atelectasis. PU has been able to document septations within effusions, which suggest that the effusion is an exudate. PU has also provided information on the presence of pleural nodules and their relationship with the pulmonary parenchyma. Most importantly, PULC changed the pathological stage of 1 patient from IIIB to IV, which changed the treatment plan for this patient [7] .
Ultrasonography is an operator-dependent technique. The mean time of 15 ± 7 min required to perform PULC examination in this study could potentially be shortened in routine clinical practice as evaluators gain experience with this imaging modality.
Pleural carcinomatosis is typically ipsilateral to the primary pulmonary malignancy [14] , and this is in keeping with our data. Cytological analysis yielded malignant cells in 1 of the 3 collected aspirates. There were 10 previously unassessed pleural effusions discovered in 26 patients with documented primary lung cancer (Table 4) . These results are similar to those of Brinkman [10] who demonstrated 1 positive cytology of 6 pleural aspirates in a group of 21 patients with otherwise operable lung carcinomas.
When assessing pleural effusions in a lung cancer patient population, one has to consider the possibility of encountering paramalignant effusions, that is, effusions caused by secondary atelectasis, pneumonia, venous or lymphatic obstruction, chylothorax or hypoalbuminaemia [3] . Among 3 patients with documented hypoalbuminaemia at the time of the PULC examination, only 1 had an echographically demonstrated pleural effusion. It is worth mentioning that this effusion displayed echogenic septa, a feature that is not usually associated with transudates caused by hypoalbuminaemia. Cytological assessment of pleural fluid was negative in this patient. Of the 6 patients displaying atelectatic phenomena on baseline CT imaging, only 2 demonstrated a pleural effusion on ultrasonography. One of these 2 patients underwent pleural aspiration that yielded a negative cytology. No pneumonia, obstructive phenomenon or chylothorax was demonstrated preoperatively among the study participants. In this context, paramalignant effusion remains a diagnosis of exclusion until surgery. Operative findings have not suggested this entity to be a confounding factor in our cohort. No pleural effusion was found in the 2 patients affected with documented connective tissue disease. Furthermore, the patient with pleural plaques related to asbestos exposure on ultrasonographic examination had no associated pleural effusion. Therefore, non-cancerous aetiologies of pleural effusion did not confound the results in this cohort.
A major limiting factor of the study is the low number of patients relative to the prevalence of sufficiently large pleural effusions for aspiration, thus restricting the number of pleural fluid samplings performed, and with it, the yield of PULC in demonstrating malignant effusions as established by positive cytology. From a technical standpoint, PULC can be limited in its sensitivity by fat in the context of an obese patient [8] . Two aspirates of three were inferior to 20 ml, suboptimal volumes that might have decreased the sensitivity of cytological analysis, causing underestimation of malignant effusions [9] . Also worthy of mention is the fact that cytology has been reported to yield diagnosis in only 67% of metastatic lung cancers [15] , a low sensitivity that could have led malignant pleural effusions to remain underdiagnosed and tumoural stages underestimated in the present study. According to the American Thoracic Society, the use of immunohistochemical markers for carcino-embryonic antigen, Leu-1 and mucin might have increased the sensitivity of the cytological analyses in this study, had they been employed, as they are often positive in adenocarcinomas [3] . Various sources in the literature state that a negative cytology warrants a second pleural tap [2, 12] , before proceeding to medical thoracoscopy or VATS; this second tap was not performed in our study and did not affect outcomes as no patient who was operated on had pleural metastasis during operative exploration of the thoracic cavity post-PULC examination.
The strengths of the study include its prospective methodology and relatively uniform patient population. The study's main limitation was its relatively small sample size considering the diagnostic endpoints.
In conclusion, preoperative PU as an adjunct to physical examination in the initial thoracic surgical clinical encounter is a rapid and effective method to improve precision of preoperative staging in patients with lung cancer. PULC can change clinical and pathological staging. More specifically, a PULC-assessed pleural effusion, although negative for malignant cells on cytology, does give the surgeon the potential to choose VATS as a first surgical approach for resection, as well as plan for peroperative fluid collection and analysis. Additionally, PULC-assessed pleural effusion with malignant cells on cytological examination, signifying a pathological upgrade of pathological staging to Stage IV, reorients patient care to medical as opposed to surgical management. Improved staging of lung cancer during first surgical encounter thus allows for early decisions about treatment plans and can help to avoid unnecessary surgery or testing in advanced disease.
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